Bio-Rad Laboratories vs Qiagen

Bio-Rad Laboratories (BIO), health care, and Qiagen (QGEN), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Qiagen is worth $10.3B on the stock market and Bio-Rad Laboratories $9.6B: Qiagen is valued at 7% more. Bio-Rad Laboratories trades at 9.5 times earnings and Qiagen at 26.9; operating margins in their latest fiscal years were 1.83% and 22.3%. Over the past year Bio-Rad Laboratories's share price has moved +17.1% and Qiagen's +12.3%.

Key facts

Bio-Rad Laboratories market value
$9.6B
Qiagen market value
$10.3B
Bio-Rad Laboratories P/E
9.5
Qiagen P/E
26.9
Bio-Rad Laboratories revenue
$2.6BFY to 2025-12-31
Qiagen revenue
$2.1BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Bio-Rad Laboratories vs Qiagen: every measure side by side
Measure Bio-Rad Laboratories Qiagen
SectorHealth CareHealth Care
Country United States Netherlands
Fiscal year ends2025-12-312025-12-31
Size
Market cap$9.6Blower$10.3Bhigher
Revenue$2.6Bhigher$2.1Blower
Earnings$759.9Mhigher$424.9Mlower
Employees7,450higher5,400lower
Total assets$10.6Bhigher$6.3Blower
Valuation
P/E9.5lower26.9higher
P/S3.7lower4.9higher
P/B1.3—
Dividend yield0.00%—
Profitability
Operating margin1.83%lower22.3%higher
Balance sheet
Net assets$7.5Bhigher$3.8Blower
Total liabilities$3.1Bhigher$2.5Blower
Total debt$1.2Blower$1.7Bhigher
Cash on hand$529.8Mlower$839Mhigher
Price change
Today-0.57%lower-0.12%higher
1 year+17.1%higher+12.3%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Bio-Rad Laboratories only (3)

Qiagen only (0)

None of the tracked investors.

Percentages are each holding's share of that investor's reported portfolio. Who owns BIO

Further comparisons

Learn

Questions and answers

Which is bigger, Bio-Rad Laboratories or Qiagen?

By market value, Qiagen is the larger: $10.3B against $9.6B for Bio-Rad Laboratories. By revenue in its latest fiscal year, Bio-Rad Laboratories is the larger: $2.6B against $2.1B for Qiagen.

Which has the higher P/E ratio?

Qiagen: 26.9, against 9.5 for Bio-Rad Laboratories. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Qiagen: 22.3%, against 1.83% for Bio-Rad Laboratories. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has more debt?

Qiagen: $1.7B, against $1.2B for Bio-Rad Laboratories. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Bio-Rad Laboratories and Qiagen?

None of the tracked superinvestors holds both in their latest 13F filing. 3 hold Bio-Rad Laboratories and 0 hold Qiagen.

Cite this page

Funkfolio, “Bio-Rad Laboratories vs Qiagen”, data as of 18 November 2026. https://funkfolio.com/compare/bio-vs-qgen

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.